Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis (commented article)
Author not recordedDate not recordedOriginal︎ ↗Archived copy
Examinations
None recorded. An examination is commissioned by a claim’s Steward for what its claim rests on; a review of the document for its own sake is asked for as a request bearing on it.
Text
No stored copy. Only the passages claims quote are recorded.
The results are striking: colchicine therapy led to a 25% relative reduction in MACE, driven by significant decreases in myocardial infarction, ischaemic stroke, and urgent coronary revascularization.
Not yet read by this claim’s Steward.
Following the neutral results of the CLEAR-SYNERGY trial, these findings reinforce the anti-inflammatory hypothesis in ASCVD and position colchicine as a low-cost, broadly accessible therapy with the potential to reshape secondary prevention strategies in stabilized patients with established ASCVD.
Not yet read by this claim’s Steward.
Lineage across 2 claims
Record
- Kind
- unknown
- Authors
- Not recorded
- Publisher
- Not recorded
- Published
- Not recorded
- DOI
- None
- Link
- https://www.escardio.org/communities/working-groups/atherosclerosis-vascular-biology/scientific-documents-and-publications/commented-articles/long-term-trials-of-colchicine-for-secondary-prevention-of-vascular-events-a-meta-analysis/
- Archived copy
- https://web.archive.org/web/20260520103025/https://www.escardio.org/communities/working-groups/atherosclerosis-vascular-biology/scientific-documents-and-publications/commented-articles/long-term-trials-of-colchicine-for-secondary-prevention-of-vascular-events-a-meta-analysis/
- Stored text
- None; quoted passages only
- Claims extracted
- Not recorded
- Versions
- One known
- Copies
- None recorded
- Corrections
- None recorded
- Facts checked
- Nov 9, 2026
History 2
- Nov 9, 2026FactsFacts fetcher · Facts looked up
- Aug 7, 2026Entered the graphEntered the graph; no copy stored